Skip to main content
. 2016 Dec 3;5(4):231–239. doi: 10.1159/000452623

Fig. 3.

Fig. 3

a Active inflammation at the left neck before rituximab (SUVmax, 6.5). b Decrease in inflammation at the left neck 6 weeks after rituximab (SUVmax, 5.2). c Persistent decrease in inflammation at the left neck 10 months after rituximab (SUVmax, 3.7). d Active inflammation at the mediastinum before rituximab (SUVmax, 8.8). e Decrease in inflammation at the mediastinum 6 weeks after rituximab (SUVmax, 4.9). f Persistent decrease in inflammation at the mediastinum 10 months after rituximab (SUVmax, 4.2). Reproduced from Soh et al. [50] with permission.